MedPath

Evaluating Immune Function Tests in People With HIV

Completed
Conditions
HIV Infections
Registration Number
NCT00067795
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Brief Summary

Some people's immune systems are able to control HIV infection without anti-HIV drugs. Other people with HIV must take drugs to prevent the virus from destroying their immune systems. There are many different laboratory tests that measure immune function in people with HIV. This study will compare some of these tests to see if they consistently measure differences between people who control the HIV without anti-HIV drugs and those who must take drugs.

Detailed Description

The efficiency of the immune response to HIV antigens is the critical feature that allows some individuals with chronic HIV infection to maintain low level viremia (less than 3000 copies/ml). The fundamental measurement of this response is the steady state level of viremia in the absence of antiretroviral drugs. However, using this clinical endpoint in vaccine and drug trials is time-consuming. Several laboratory assays of HIV T cell function have been developed to measure the key characteristics of an efficient immune response. This study will evaluate these assays in two distinct patient populations.

Two patient cohorts will be followed in this study. Cohort A will enroll patients who are stable on highly active antiretroviral therapy (HAART). These patients will have been on the same HAART regimen for at least 9 months prior to study entry. Cohort B will enroll patients with chronic HIV infection and efficient immune control. These patients will have not been on any antiretroviral drugs for at least 6 months and will have viral loads less than 3,000 copies/ml. Participants in both cohorts will have blood drawn at study entry and Weeks 12 and 24. Blood samples will be used for CD4/CD8 cell count, plasma HIV-1 RNA, and immunologic assays.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
54
Inclusion Criteria

Not provided

Exclusion Criteria
  • Pregnancy or breast-feeding
  • Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements
  • History of an AIDS-defining opportunistic infection

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (6)

Case Western Reserve University

🇺🇸

Cleveland, Ohio, United States

University of Pittsburgh

🇺🇸

Pittsburgh, Pennsylvania, United States

UC Davis Medical Center

🇺🇸

Sacremento, California, United States

University of Alabama at Birmingham

🇺🇸

Birmingham, Alabama, United States

Rush-Presbyterian/St. Lukes

🇺🇸

Chicago, Illinois, United States

University of Miami

🇺🇸

Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath